DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Stilgenbauer S, Zenz T, Winkler D et al.
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
J Clin Oncol 2009;
27: 3994-4001
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.